Latest News

EU Fragrance Allergen Rules: More Than a Labelling Change

EU Fragrance Allergen Rules: More Than a Labelling Change

At first glance, the EU’s updated rules on fragrance allergens seem straightforward. More ingredients need to be listed on cosmetic labels. For formulators and brands, though, the real work begins long before the label is printed. It starts with supplier data, runs...

read more

Latest News

Alzheimer’s Blood Tests: How Close Is Routine Screening?

Alzheimer’s Blood Tests: How Close Is Routine Screening?

For decades, confirming Alzheimer’s pathology meant an amyloid PET scan or a lumbar puncture. In 15 months, US regulators have cleared four blood tests that can do a similar job from a blood draw. Yet each Alzheimer’s blood test now on the US market is a diagnostic...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Why Medical Electronics Are the Hardest E-Waste to Recycle

Why Medical Electronics Are the Hardest E-Waste to Recycle

Single-use medical electronics are one of the fastest-growing sources of electronic waste, yet almost none of their metals or batteries are recovered. The barrier is not technology. It is contamination, and the cost that comes with it. Every week or two, millions of...

read more
Weekly News Roundup | 9 November 2026

Weekly News Roundup | 9 November 2026

Life science news 9 November 2026: two US regulatory decisions, three UK updates, two licensing deals and one acquisition. The FDA granted accelerated approval to Rybrevant Faspro for head and neck cancer. AbbVie licensed an oral IBD candidate from Nxera in a deal...

read more
Zolgensma Tumour Risk: Does the Gene Therapy Cause Tumours?

Zolgensma Tumour Risk: Does the Gene Therapy Cause Tumours?

Zolgensma tumour risk moved from a label warning to a reported safety signal on 5 November 2026. Novartis said it had received nine tumour reports in treated patients since the 2019 approval. In two cases, the company said, there is evidence that vector DNA integrated...

read more
Clinical Trial Results 6 November 2026

Clinical Trial Results 6 November 2026

The clinical trial results 6 November 2026 span immune thrombocytopenia, anaemia in chronic kidney disease, red cell transfusion and pterygium. InnoCare’s orelabrutinib met its primary endpoint in chronic primary immune thrombocytopenia. Akebia’s three-times-weekly...

read more
Hygiene Poverty and the Overlooked Toileting Needs of Women

Hygiene Poverty and the Overlooked Toileting Needs of Women

If you had to choose between food and toilet paper, what would you choose? A UK report from In Kind Direct and The Hygiene Bank found that 47% of people experiencing hygiene poverty had gone without toilet roll, making it the most common product people went without....

read more
Why Medical Electronics Are the Hardest E-Waste to Recycle

Why Medical Electronics Are the Hardest E-Waste to Recycle

Single-use medical electronics are one of the fastest-growing sources of electronic waste, yet almost none of their metals or batteries are recovered. The barrier is not technology. It is contamination, and the cost that comes with it. Every week or two, millions of...

read more
Weekly News Roundup | 9 November 2026

Weekly News Roundup | 9 November 2026

Life science news 9 November 2026: two US regulatory decisions, three UK updates, two licensing deals and one acquisition. The FDA granted accelerated approval to Rybrevant Faspro for head and neck cancer. AbbVie licensed an oral IBD candidate from Nxera in a deal...

read more
Zolgensma Tumour Risk: Does the Gene Therapy Cause Tumours?

Zolgensma Tumour Risk: Does the Gene Therapy Cause Tumours?

Zolgensma tumour risk moved from a label warning to a reported safety signal on 5 November 2026. Novartis said it had received nine tumour reports in treated patients since the 2019 approval. In two cases, the company said, there is evidence that vector DNA integrated...

read more
Clinical Trial Results 6 November 2026

Clinical Trial Results 6 November 2026

The clinical trial results 6 November 2026 span immune thrombocytopenia, anaemia in chronic kidney disease, red cell transfusion and pterygium. InnoCare’s orelabrutinib met its primary endpoint in chronic primary immune thrombocytopenia. Akebia’s three-times-weekly...

read more
Hygiene Poverty and the Overlooked Toileting Needs of Women

Hygiene Poverty and the Overlooked Toileting Needs of Women

If you had to choose between food and toilet paper, what would you choose? A UK report from In Kind Direct and The Hygiene Bank found that 47% of people experiencing hygiene poverty had gone without toilet roll, making it the most common product people went without....

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Rethinking Biologics Plants to Earn Attractive Returns

Rethinking Biologics Plants to Earn Attractive Returns

The rapid growth of biologics and other advanced therapeutic modalities is transforming pharmaceutical R&D and manufacturing. From monoclonal antibodies and oligonucleotides to cell and gene therapies, these products introduce a level of process complexity,...

read more
ObesityWeek 2026 Preview: The Data to Watch in Washington

ObesityWeek 2026 Preview: The Data to Watch in Washington

ObesityWeek 2026 runs from 14 to 17 November in National Harbor, Maryland, just outside Washington. The meeting is The Obesity Society’s 44th annual gathering. Novo Nordisk arrives with 26 abstracts, including the first results from REDEFINE 9, its lower-dose...

read more

Further News

What It Takes To Move Biomanufacturing Toward Commercial Scale

Scientific breakthroughs get attention for good reason. They are the moments when something that did not exist before suddenly becomes possible. But anyone who has spent time trying to commercialize biotechnology learns another lesson pretty quickly: proving that...

GLP-1 Vision Loss: What Does the FDA’s New NAION Warning Mean?

The FDA now requires every GLP-1 receptor agonist label to carry a warning about a rare eye condition. The condition is non-arteritic anterior ischaemic optic neuropathy, or NAION. The agency announced the change in a drug safety communication on 9 November 2026. For...

ANI Egetis Offer: What Is ANI Paying and When Could It Close?

ANI Pharmaceuticals is offering SEK 11.25 in cash for each share in Egetis Therapeutics. ANI puts the total value of the ANI Egetis offer at about SEK 5.6 billion, or about $560 million. The offer was announced on 5 November 2026 and has not completed. The acceptance...

The Healthcare AI That Wins Won’t Be the One With the Best Demo

Healthcare has no shortage of impressive AI demos. Scaling healthcare AI is another matter. A model can summarize a chart in seconds. An ambient tool can generate a clinical note from a conversation. An AI agent can identify a denied claim or suggest the next...

Lilly vs Novo in 2026: How the Obesity Market Has Shifted

Lilly vs Novo is the rivalry that defines obesity medicine, and 2026 has redrawn the balance between the two companies. Third-quarter results published on 29 October and 4 November show Eli Lilly growing at a scale few drugmakers have reached. Novo Nordisk, meanwhile,...

Povetacicept FDA Decision: Will Vertex Win Approval by 30 November?

The povetacicept FDA decision is due by 30 November 2026. The evidence points towards a plausible approval but does not settle it. Vertex Pharmaceuticals says its application for accelerated approval in IgA nephropathy (IgAN) is under priority review. The company’s...

The Signature Is the Safeguard: Where AI Belongs in Mental Health Care

Most of the argument about AI in mental health care is about chatbots that talk like therapists. The bigger change is happening somewhere less visible: in the notes, forms and insurance paperwork that sit between a clinician and the next person they are trying to...

Why Medical Electronics Are the Hardest E-Waste to Recycle

Single-use medical electronics are one of the fastest-growing sources of electronic waste, yet almost none of their metals or batteries are recovered. The barrier is not technology. It is contamination, and the cost that comes with it. Every week or two, millions of...

Weekly News Roundup | 9 November 2026

Life science news 9 November 2026: two US regulatory decisions, three UK updates, two licensing deals and one acquisition. The FDA granted accelerated approval to Rybrevant Faspro for head and neck cancer. AbbVie licensed an oral IBD candidate from Nxera in a deal...

Zolgensma Tumour Risk: Does the Gene Therapy Cause Tumours?

Zolgensma tumour risk: Novartis reports nine tumour cases, two with vector integration evidence. What the labels say and what is unknown.

    What Happened When We Gave Business Classes Our Real Production Data

    At Karviva, we used several Google Sheets to keep track of ingredients, materials, production and orders. As the business grew, keeping those records connected became harder. We needed to plan production more reliably and trace each batch from its ingredients through...

    Clinical Trial Results 6 November 2026

    The clinical trial results 6 November 2026 span immune thrombocytopenia, anaemia in chronic kidney disease, red cell transfusion and pterygium. InnoCare’s orelabrutinib met its primary endpoint in chronic primary immune thrombocytopenia. Akebia’s three-times-weekly...

    Want to Be Part of the Next Chapter in Life Sciences Media?

     

    LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

     

     

    Don’t wait for the media to pick up your story. Be the media.

    See More Articles

    Want to Be Part of the Next Chapter in Life Sciences Media?

     

    LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

     

     

    Don’t wait for the media to pick up your story. Be the media.